MCID: THY124
MIFTS: 38

Thyroid Gland Papillary Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Gland Papillary Carcinoma

MalaCards integrated aliases for Thyroid Gland Papillary Carcinoma:

Name: Thyroid Gland Papillary Carcinoma 12 15
Papillary Carcinoma of the Thyroid Gland 12
Thyroid Cancer, Papillary 43

Classifications:



External Ids:

Disease Ontology 12 DOID:3969
MeSH 43 D000077273
NCIt 49 C4035
SNOMED-CT 67 255029007
UMLS 71 C0238463

Summaries for Thyroid Gland Papillary Carcinoma

Disease Ontology : 12 A differentiated thyroid gland carcinoma that is characterized by the small mushroom shape of the tumor which has a stem attached to the epithelial layer abd arises from the follicular cells of the thyroid gland.

MalaCards based summary : Thyroid Gland Papillary Carcinoma, also known as papillary carcinoma of the thyroid gland, is related to multicentric papillary thyroid carcinoma and columnar cell variant papillary carcinoma. An important gene associated with Thyroid Gland Papillary Carcinoma is CRNDE (Colorectal Neoplasia Differentially Expressed). The drugs Iodine and cadexomer iodine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and lung.

Related Diseases for Thyroid Gland Papillary Carcinoma

Diseases related to Thyroid Gland Papillary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 multicentric papillary thyroid carcinoma 11.5
2 columnar cell variant papillary carcinoma 11.5
3 tall cell variant papillary carcinoma 11.5
4 papillary carcinoma 10.6
5 goiter 10.4
6 thyroiditis 10.4
7 thyroid tumor 10.3
8 differentiated thyroid carcinoma 10.2
9 thyroid carcinoma 10.2
10 thyroid carcinoma, familial medullary 10.2
11 hypoparathyroidism 10.2
12 thyroid gland medullary carcinoma 10.2
13 adenoma 10.2
14 pseudosarcomatous fibromatosis 10.2
15 fasciitis 10.2
16 pheochromocytoma 10.0
17 graves disease 1 10.0
18 oncocytoma 10.0
19 parathyroid carcinoma 10.0
20 multinodular goiter 10.0
21 fibroma 10.0
22 adrenal gland pheochromocytoma 10.0
23 adenoid cystic carcinoma 10.0
24 neutropenia 10.0
25 lymphadenitis 10.0
26 pericarditis 10.0
27 leiomyosarcoma 10.0
28 pulmonary tuberculosis 10.0
29 adenocarcinoma 10.0
30 multiple endocrine neoplasia 10.0
31 tracheal stenosis 10.0
32 mixed connective tissue disease 10.0
33 systemic scleroderma 10.0
34 paraplegia 10.0
35 follicular adenoma 10.0
36 connective tissue disease 10.0
37 b-cell lymphoma 10.0
38 hyperthyroidism 10.0
39 lung disease 10.0
40 neurofibroma 10.0
41 raynaud phenomenon 10.0
42 dysphagia 10.0
43 rapidly involuting congenital hemangioma 10.0
44 thyroid cancer, nonmedullary, 1 10.0
45 insulin-like growth factor i 10.0
46 hypothyroidism 10.0
47 thyroid gland disease 10.0
48 fibromatosis 10.0
49 papillary thyroid microcarcinoma 9.9
50 graves' disease 9.9

Graphical network of the top 20 diseases related to Thyroid Gland Papillary Carcinoma:



Diseases related to Thyroid Gland Papillary Carcinoma

Symptoms & Phenotypes for Thyroid Gland Papillary Carcinoma

Drugs & Therapeutics for Thyroid Gland Papillary Carcinoma

Drugs for Thyroid Gland Papillary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 2, Phase 3 7553-56-2 807
2 cadexomer iodine Phase 2, Phase 3
3
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556
4
leucovorin Approved Phase 2 58-05-9 6006 143
5
Vemurafenib Approved Phase 2 918504-65-1 23252090 42611257
6
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
7
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
8
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
9
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
10
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
11
Entrectinib Approved, Investigational Phase 2 1108743-60-7 25141092
12
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
13
Durvalumab Approved, Investigational Phase 2 1428935-60-7
14
Ipilimumab Approved Phase 2 477202-00-9
15
nivolumab Approved Phase 2 946414-94-4
16
Pembrolizumab Approved Phase 2 1374853-91-4
17
Lenvatinib Approved, Investigational Phase 2 417716-92-8
18
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
19
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
20
Trametinib Approved Phase 2 871700-17-3 11707110
21
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
22
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
23
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
25
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
26
Imetelstat Investigational Phase 2 868169-64-6
27
Tremelimumab Investigational Phase 2 745013-59-6
28
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
29
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
30
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
31 Vitamin B Complex Phase 2
32 Folic Acid Antagonists Phase 2
33 Tubulin Modulators Phase 2
34 Folate Phase 2
35 Vitamin B9 Phase 2
36 Antimitotic Agents Phase 2
37 Mitogens Phase 2
38 Endothelial Growth Factors Phase 2
39
Motesanib diphosphate Phase 2 850649-62-6 11450633
40 Histone Deacetylase Inhibitors Phase 2
41 Anti-Bacterial Agents Phase 2
42 Antibiotics, Antitubercular Phase 2
43 Antimetabolites Phase 2
44 Liver Extracts Phase 2
45 Fluorides Phase 2
46 Deoxyglucose Phase 2
47 Antiviral Agents Phase 2
48 Cola Phase 1, Phase 2
49 Immunoglobulins Phase 2
50 Antibodies Phase 2

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) Completed NCT01083550 Phase 2, Phase 3
2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
3 Phase 2 Trial of Pemetrexed (Alimta™) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer Unknown status NCT00786552 Phase 2 pemetrexed + paclitaxel
4 An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine Completed NCT01286753 Phase 2 Vemurafenib
5 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
6 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
7 Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma Completed NCT00134043 Phase 2 vorinostat
8 Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation Completed NCT00519896 Phase 2 sunitinib malate
9 Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements Completed NCT00559949 Phase 2 Selumetinib
10 A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma Completed NCT00104871 Phase 2 Bortezomib
11 A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma Completed NCT00098813 Phase 2 romidepsin
12 A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma Completed NCT00118248 Phase 2 tanespimycin
13 Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine Completed NCT00085293 Phase 2 Decitabine
14 A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma Completed NCT01502410 Phase 2 sorafenib tosylate
15 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
16 A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy Completed NCT00729157 Phase 2
17 Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma Completed NCT00887107 Phase 2 Sorafenib (nexavar)
18 Randomized Controlled Trial of Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in Patients With Low-risk Papillary Thyroid Cancer Completed NCT02408887 Phase 2
19 A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
20 An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements Recruiting NCT02568267 Phase 2 Entrectinib
21 A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
22 A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
23 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
24 A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) Recruiting NCT03157128 Phase 1, Phase 2 LOXO-292 (selpercatinib)
25 Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy Recruiting NCT03914300 Phase 2 Cabozantinib S-malate
26 A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers Recruiting NCT02152995 Phase 2 Trametinib
27 Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study Active, not recruiting NCT02973997 Phase 2 Lenvatinib
28 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
29 A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
30 Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer Active, not recruiting NCT02138214 Phase 2
31 Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers Active, not recruiting NCT02393690 Phase 2 Selumetinib
32 Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib;Cediranib Maleate;Lenalidomide
33 Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer Active, not recruiting NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
34 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma Terminated NCT00095693 Phase 2 sorafenib tosylate
35 A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors Completed NCT00451880 Phase 1 XL281;famotidine
36 A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
37 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
38 A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake Completed NCT01413113 Phase 1 pazopanib hydrochloride
39 Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Imaging: a Multicentre Feasibility and Completed NCT03470259 Phase 1 IV adminstration of EMI-137
40 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
41 A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer Patients Recruiting NCT03469011 Phase 1 Imatinib Oral Tablet
42 99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study Unknown status NCT00984191
43 Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma Unknown status NCT02648399
44 Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma Unknown status NCT01417442 Early Phase 1
45 Differences Protein Expression in Papillary Thyroid Carcinoma Unknown status NCT02814032
46 Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial Unknown status NCT02140476
47 Assessment of Serum Leptin Levels in Females With Papillary Thyroid Carcinoma, Benign Thyroid Nodules, and Normal Controls Completed NCT01659385
48 Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy Completed NCT01354639
49 Immunohistochemical Detection of the BRAFV600E Mutation on Cytological Specimen in PTC Completed NCT02561533
50 The Effectiveness of Prophylactic Selective Lateral Neck Dissection in Papillary Thyroid Carcinoma Patients With Central Neck Metastasis Completed NCT01103557

Search NIH Clinical Center for Thyroid Gland Papillary Carcinoma

Cochrane evidence based reviews: thyroid cancer, papillary

Genetic Tests for Thyroid Gland Papillary Carcinoma

Anatomical Context for Thyroid Gland Papillary Carcinoma

MalaCards organs/tissues related to Thyroid Gland Papillary Carcinoma:

40
Thyroid, Lymph Node, Lung, Breast, Testes, Liver, Endothelial

Publications for Thyroid Gland Papillary Carcinoma

Articles related to Thyroid Gland Papillary Carcinoma:

(show top 50) (show all 65)
# Title Authors PMID Year
1
Leukocyte immunoglobulin-like receptor subfamily B member 1 potentially acts as a diagnostic and prognostic target in certain subtypes of adenocarcinoma. 61
32534335 2020
2
Study of Essential and Toxic Metal Imbalances in the Scalp Hair of Thyroid Cancer Patients in Comparison with Healthy Donors. 61
32405688 2020
3
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. 61
32182156 2020
4
Papillary carcinoma in correlation to thyroidal duct cyst: A case series. 61
32042395 2020
5
The features of contrast enhanced ultrasound and BRAF V600E in papillary thyroid carcinoma. 61
32030223 2019
6
Low prevalence of symptomatic thyroid diseases and thyroid cancers in HIV-infected patients. 61
31857648 2019
7
Thyroid disease and cancer in kidney transplantation: a single-center analysis. 61
31074392 2019
8
Unusual Metastases in Papillary Microcarcinoma of Thyroid. 61
30713376 2019
9
[Treatment of Brain Metastases from Papillary Thyroid Carcinomas:Five Surgical Cases in Our Hospital and a Literature Review]. 61
30458434 2018
10
Effect of a Change in Papillary Thyroid Cancer Terminology on Anxiety Levels and Treatment Preferences: A Randomized Crossover Trial. 61
30335875 2018
11
Inhibitory roles of miR‑9 on papillary thyroid cancer through targeting BRAF. 61
29767243 2018
12
Molecular markers in well-differentiated thyroid cancer. 61
29626249 2018
13
lncRNA BANCR promotes EMT in PTC via the Raf/MEK/ERK signaling pathway. 61
29552216 2018
14
Thrombosis in Thyroid Cancer. 61
29696039 2018
15
Investigating the mechanisms of papillary thyroid carcinoma using transcriptome analysis. 61
28849102 2017
16
Epigenetic Modifications: Novel Therapeutic Approach for Thyroid Cancer. 61
28956361 2017
17
Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. 61
28476040 2017
18
Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer. 61
28141684 2017
19
A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. 61
28207834 2017
20
[A Familial Non Medullary Thyroid Carcinoma (FNMTC) : a clinical and genetic update]. 61
28387096 2016
21
Aurora kinase A induces papillary thyroid cancer lymph node metastasis by promoting cofilin-1 activity. 61
27003257 2016
22
Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). 61
26427660 2016
23
[The management of laryngotracheal defect derived from thyroid gland papillary carcinoma resection]. 61
26211155 2015
24
The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. 61
24946010 2014
25
Predictive factors of thyroid cancer in patients with Graves' disease. 61
24166025 2014
26
MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology. 61
25202329 2014
27
Malignant thyroglossal duct cyst with synchronous occult thyroid gland papillary carcinoma. 61
24083187 2013
28
The increasing incidence of thyroid cancer: the influence of access to care. 61
23517343 2013
29
Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. 61
24155971 2013
30
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. 61
22932786 2012
31
Sorafenib in metastatic thyroid cancer. 61
22285864 2012
32
Thyroid cancer in patients with hyperthyroidism. 61
22334393 2012
33
Familial follicular cell-derived thyroid carcinoma. 61
22654876 2012
34
Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. 61
23077520 2012
35
Thyroid cancer: is ethnicity relevant? 61
21729457 2011
36
Familial follicular cell tumors: classification and morphological characteristics. 61
20878367 2010
37
Multifocality of thyroid carcinomas: a "privilege" of papillary tumors or not? 61
20298661 2010
38
[Surgery of thyroid carcinoma]. 61
19902289 2009
39
Anthropometric factors at age 20 years and risk of thyroid cancer. 61
18618280 2008
40
The therapeutic management of differentiated thyroid cancer. 61
18803450 2008
41
Metastatic adenocarcinoma to the cervical lymph node: a significant proportion of cholangiocarcinoma in Thai patients. 61
18439070 2008
42
New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. 61
18045949 2007
43
Advanced thyroid carcinoma: an experience of 385 cases. 61
16644177 2006
44
[Pathogenesis of differentiated thyroid cancer (papillary and follicular)]. 61
16444351 2005
45
Papillary thyroid cancer: medical management and follow-up. 61
15967085 2005
46
[Confronting the practice of surgery on differentiated thyroid cancer with current guidelines in Germany. A multicenter trial]. 61
16395493 2005
47
[Completing total thyroidectomy with lymph node dissection using a scintillation probe--case report]. 61
15216687 2004
48
[Surgical strategies in the diagnosis and treatment of patients with differentiated thyroid cancer]. 61
15143574 2004
49
Tumors of thyroid follicular epithelium: where have we been and where are we going?. 61
12665645 2002
50
Estrogen and progesterone receptors in neoplastic and non-neoplastic thyroid lesions. 61
12140869 2002

Variations for Thyroid Gland Papillary Carcinoma

Cosmic variations for Thyroid Gland Papillary Carcinoma:

9 (show top 50) (show all 3512)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149314757 ZFHX3 thyroid,NS,carcinoma,papillary carcinoma c.5539C>T p.Q1847* 16:72797143-72797143 15
2 COSM89410732 ZBTB2 thyroid,NS,carcinoma,papillary carcinoma c.1012C>G p.P338A 6:151366054-151366054 15
3 COSM101976985 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.994G>T p.E332* 2:61495508-61495508 15
4 COSM101980763 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.1801C>G p.Q601E 2:61492121-61492121 15
5 COSM91385851 WT1 thyroid,NS,carcinoma,papillary carcinoma c.698C>G p.S233W 11:32428568-32428568 15
6 COSM96873846 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.399C>G p.I133M 1:117156620-117156620 15
7 COSM88292485 VHL thyroid,NS,carcinoma,papillary carcinoma c.241C>T p.P81S 3:10142088-10142088 15
8 COSM131082360 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1358T>C p.M453T 14:81143416-81143416 15
9 COSM131082578 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1867G>T p.A623S 14:81143925-81143925 15
10 COSM131089095 TSHR thyroid,NS,carcinoma,papillary carcinoma c.572C>T p.S191L 14:81096665-81096665 15
11 COSM131082573 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1868C>T p.A623V 14:81143926-81143926 15
12 COSM131083920 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1897G>T p.D633Y 14:81143955-81143955 15
13 COSM131087323 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1915C>T p.P639S 14:81143973-81143973 15
14 COSM87027692 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4433A>T p.D1478V 16:2084655-2084655 15
15 COSM87028962 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4468G>C p.E1490Q 16:2084690-2084690 15
16 COSM87049629 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4760G>A p.C1587Y 16:2086290-2086290 15
17 COSM94304986 TRRAP thyroid,NS,carcinoma,papillary carcinoma c.7726A>C p.T2576P 7:98971853-98971853 15
18 COSM99628948 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.925G>T p.E309* 15:43477623-43477623 15
19 COSM99620599 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.5480G>T p.G1827V 15:43409017-43409017 15
20 COSM87900604 TP53 thyroid,NS,carcinoma,papillary carcinoma c.637C>T p.R213* 17:7674894-7674894 15
21 COSM87899887 TP53 thyroid,NS,carcinoma,papillary carcinoma c.856G>A p.E286K 17:7673764-7673764 15
22 COSM87897687 TP53 thyroid,NS,carcinoma,papillary carcinoma c.481G>A p.A161T 17:7675131-7675131 15
23 COSM87913147 TP53 thyroid,NS,carcinoma,papillary carcinoma c.845G>A p.R282Q 17:7673775-7673775 15
24 COSM87903333 TP53 thyroid,NS,carcinoma,papillary carcinoma c.646G>A p.V216M 17:7674885-7674885 15
25 COSM87952319 TP53 thyroid,NS,carcinoma,papillary carcinoma c.670G>T p.E224* 17:7674861-7674861 15
26 COSM87935614 TP53 thyroid,NS,carcinoma,papillary carcinoma c.738G>A p.M246I 17:7674225-7674225 15
27 COSM87898723 TP53 thyroid,NS,carcinoma,papillary carcinoma c.817C>T p.R273C 17:7673803-7673803 15
28 COSM87912435 TP53 thyroid,NS,carcinoma,papillary carcinoma c.396G>C p.K132N 17:7675216-7675216 15
29 COSM87901016 TP53 thyroid,NS,carcinoma,papillary carcinoma c.734G>T p.G245V 17:7674229-7674229 15
30 COSM87897711 TP53 thyroid,NS,carcinoma,papillary carcinoma c.818G>A p.R273H 17:7673802-7673802 15
31 COSM87911941 TP53 thyroid,NS,carcinoma,papillary carcinoma c.749C>T p.P250L 17:7674214-7674214 15
32 COSM87967501 TP53 thyroid,NS,carcinoma,papillary carcinoma c.398T>C p.M133T 17:7675214-7675214 15
33 COSM87900303 TP53 thyroid,NS,carcinoma,papillary carcinoma c.638G>A p.R213Q 17:7674893-7674893 15
34 COSM87904588 TP53 thyroid,NS,carcinoma,papillary carcinoma c.374C>T p.T125M 17:7675995-7675995 15
35 COSM87905856 TP53 thyroid,NS,carcinoma,papillary carcinoma c.643A>G p.S215G 17:7674888-7674888 15
36 COSM87906968 TP53 thyroid,NS,carcinoma,papillary carcinoma c.833C>T p.P278L 17:7673787-7673787 15
37 COSM87899497 TP53 thyroid,NS,carcinoma,papillary carcinoma c.586C>T p.R196* 17:7674945-7674945 15
38 COSM87907024 TP53 thyroid,NS,carcinoma,papillary carcinoma c.799C>T p.R267W 17:7673821-7673821 15
39 COSM87898351 TP53 thyroid,NS,carcinoma,papillary carcinoma c.743G>A p.R248Q 17:7674220-7674220 15
40 COSM87898424 TP53 thyroid,NS,carcinoma,papillary carcinoma c.722C>T p.S241F 17:7674241-7674241 15
41 COSM87897883 TP53 thyroid,NS,carcinoma,papillary carcinoma c.659A>G p.Y220C 17:7674872-7674872 15
42 COSM87898714 TP53 thyroid,NS,carcinoma,papillary carcinoma c.844C>T p.R282W 17:7673776-7673776 15
43 COSM87898758 TP53 thyroid,NS,carcinoma,papillary carcinoma c.707A>G p.Y236C 17:7674256-7674256 15
44 COSM87898862 TP53 thyroid,NS,carcinoma,papillary carcinoma c.722C>G p.S241C 17:7674241-7674241 15
45 COSM87935575 TP53 thyroid,NS,carcinoma,papillary carcinoma c.528C>G p.C176W 17:7675084-7675084 15
46 COSM87899771 TP53 thyroid,NS,carcinoma,papillary carcinoma c.716A>C p.N239T 17:7674247-7674247 15
47 COSM88143179 TP53 thyroid,NS,carcinoma,papillary carcinoma c.96+1G>C p.? 17:7676381-7676381 15
48 COSM87901134 TP53 thyroid,NS,carcinoma,papillary carcinoma c.417G>C p.K139N 17:7675195-7675195 15
49 COSM87899842 TP53 thyroid,NS,carcinoma,papillary carcinoma c.584T>C p.I195T 17:7674947-7674947 15
50 COSM87985318 TP53 thyroid,NS,carcinoma,papillary carcinoma c.691A>G p.T231A 17:7674272-7674272 15

Expression for Thyroid Gland Papillary Carcinoma

Search GEO for disease gene expression data for Thyroid Gland Papillary Carcinoma.

Pathways for Thyroid Gland Papillary Carcinoma

GO Terms for Thyroid Gland Papillary Carcinoma

Sources for Thyroid Gland Papillary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....